^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Ovarian Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2021
    Title:

    740P - Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study

    Published date:
    09/13/2021
    Excerpt:
    279 pts were enrolled and received olaparib maintenance (tablets; 300 mg bid)....12% of pts (34/279) had a non-BRCA HRRm (8 RAD51C; 7 BRIP1; 7 RAD51D; 3 CDK12; 2 FANCL; 2 PALB2; 1 ATM; 1 BARD1; 1 RAD51B; 1 CHEK2 and RAD51D; 1 PPP2R2A and RAD51C).....Pts with a non-BRCA HRRm achieved longer PFS benefit compared with the non HRRm subgroup.
    Trial ID:
    OPINION
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Prostate Cancer)
    New
    Title:

    Lynparza (olaparib) Receives Health Canada Approval for the Treatment of BRCA or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

    Excerpt:
    Health Canada approved Lynparza (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).